Alison B. Fleming

630 total citations
20 papers, 525 citations indexed

About

Alison B. Fleming is a scholar working on Anesthesiology and Pain Medicine, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Alison B. Fleming has authored 20 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Anesthesiology and Pain Medicine, 10 papers in Public Health, Environmental and Occupational Health and 5 papers in Physiology. Recurrent topics in Alison B. Fleming's work include Pain Management and Opioid Use (12 papers), Opioid Use Disorder Treatment (10 papers) and Pain Mechanisms and Treatments (5 papers). Alison B. Fleming is often cited by papers focused on Pain Management and Opioid Use (12 papers), Opioid Use Disorder Treatment (10 papers) and Pain Mechanisms and Treatments (5 papers). Alison B. Fleming collaborates with scholars based in United States, Netherlands and Israel. Alison B. Fleming's co-authors include W. Mark Saltzman, Ernest A. Kopecky, Kraig Haverstick, Naama Levy‐Cooperman, Michael D. Smith, Nathaniel P. Katz, Edward M. Sellers, Robert H. Brown, Lynn R. Webster and Patrick K. Noonan and has published in prestigious journals such as Pain, Journal of Controlled Release and Clinical Pharmacokinetics.

In The Last Decade

Alison B. Fleming

20 papers receiving 505 citations

Peers

Alison B. Fleming

PHEOH

APM

BIOMA

GENET

Sophie Laurent France

Sayena Jabbehdari United States

Guoan Zhang China

Stefanie Deuster Switzerland

Jianli Hu China

David Sanford Canada

Shilpa Patil India

Ao Li China

Rui Xia China

Sophie Laurent France

Alison B. Fleming

78 ×0.4

PHEOH

117 ×0.7

APM

86 ×0.6

BIOMA

7 ×0.1

GENET

71 ×0.6

Citations per year, relative to Alison B. Fleming Alison B. Fleming (= 1×) peers Sophie Laurent

Countries citing papers authored by Alison B. Fleming

Since Specialization

Citations

This map shows the geographic impact of Alison B. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison B. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison B. Fleming more than expected).

Fields of papers citing papers by Alison B. Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison B. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison B. Fleming. The network helps show where Alison B. Fleming may publish in the future.

Co-authorship network of co-authors of Alison B. Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Alison B. Fleming. A scholar is included among the top collaborators of Alison B. Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison B. Fleming. Alison B. Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fleming, Alison B., et al.. (2017). In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations. Clinical Drug Investigation. 37(12). 1117–1124. 10 indexed citations

Butler, Stephen F., Ryan A. Black, & Alison B. Fleming. (2017). Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration. Pain Medicine. 19(8). 1613–1627. 11 indexed citations

Brennan, Michael J., et al.. (2017). The Comparative Pharmacokinetics of Physical Manipulation by Crushing of Xtampza ^® ER Compared with OxyContin ^®. Pain Management. 7(6). 461–472. 7 indexed citations

Fleming, Alison B., et al.. (2016). In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. Journal of Opioid Management. 12(1). 57–65. 13 indexed citations

McCarberg, Bill, et al.. (2016). An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia. Current Medical Research and Opinion. 32(12). 1975–1982. 11 indexed citations

Kopecky, Ernest A., et al.. (2016). Oral Human Abuse Potential of Oxycodone DETERx^®(Xtampza^®ER). The Journal of Clinical Pharmacology. 57(4). 500–512. 28 indexed citations

Webster, Lynn R., Ernest A. Kopecky, Michael D. Smith, & Alison B. Fleming. (2015). A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Medicine. 17(6). 1112–1130. 24 indexed citations

Katz, Nathaniel P., et al.. (2015). A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 156(12). 2458–2467. 28 indexed citations

Levy‐Cooperman, Naama, et al.. (2015). Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Pain Medicine. 16(11). 2142–2151. 36 indexed citations

10.

Fleming, Alison B., et al.. (2015). Evaluation of an Extended‐Release, Abuse‐Deterrent, Microsphere‐in‐Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD). Pain Practice. 16(3). 334–344. 14 indexed citations

11.

Kopecky, Ernest A., et al.. (2015). (445) Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study. Journal of Pain. 16(4). S87–S87. 2 indexed citations

12.

Kopecky, Ernest A., et al.. (2014). Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: An extended-release, abuse-deterrent formulation. Journal of Opioid Management. 10(4). 233–246. 29 indexed citations

13.

Kopecky, Ernest A., et al.. (2014). (459) Oxycodone DETERx, an extended-release, abuse-deterrent formulation for management of patients with chronic pain and chronic pain with dysphagia. Journal of Pain. 15(4). S90–S90. 3 indexed citations

14.

Fleming, Alison B., et al.. (2014). Safety and pharmacokinetics of oxycodone DETERx administered intranasally in recreational opioid users. Drug and Alcohol Dependence. 146. e163–e163. 1 indexed citations

15.

Kopecky, Ernest A., et al.. (2013). Oxycodone DETERx, an extended-release, tamper-resistant formulation for management of chronic pain. Journal of Pain. 14(4). S68–S68. 2 indexed citations

16.

Fleming, Alison B., Patrick K. Noonan, & Anthony H. Wheeler. (2008). (281) Abuse-deterrent properties and pharmacokinetics of a novel sustained release formulation of oxycodone for the treatment of moderate to severe pain. Journal of Pain. 9(4). 46–46. 2 indexed citations

17.

Haverstick, Kraig, Alison B. Fleming, & W. Mark Saltzman. (2007). Conjugation to Increase Treatment Volume during Local Therapy: A Case Study with PEGylated Camptothecin. Bioconjugate Chemistry. 18(6). 2115–2121. 11 indexed citations

18.

Fleming, Alison B., Kraig Haverstick, & W. Mark Saltzman. (2004). In Vitro Cytotoxicity and in Vivo Distribution after Direct Delivery of PEG−Camptothecin Conjugates to the Rat Brain. Bioconjugate Chemistry. 15(6). 1364–1375. 57 indexed citations

19.

Fleming, Alison B. & W. Mark Saltzman. (2002). Pharmacokinetics of the Carmustine Implant. Clinical Pharmacokinetics. 41(6). 403–419. 226 indexed citations

20.

Fleming, Alison B. & W. Mark Saltzman. (2001). Simultaneous delivery of an active protein and neutralizing antibody: creation of separated regions of biological activity. Journal of Controlled Release. 70(1-2). 29–36. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact